| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Collagen‑induced thromboxane A₂ (TXA₂) production (measured as its stable metabolite TXB₂).[1]
|
|---|---|
| ln Vivo |
- Jujuboside B (30, 100, 300 μM) concentration‑dependently inhibited collagen (2 μg/ml)‑induced platelet aggregation. Jujuboside A at the same concentrations showed no effect. [1]
- Jujuboside B also dose‑dependently inhibited thrombin (0.4 U/ml)‑, arachidonic acid (AA, 100 μM)‑, and ADP (10 μM)‑induced platelet aggregations. [1] - The IC₅₀ values of Jujuboside B for inhibiting platelet aggregation were: collagen – 128.3 μM; thrombin – 280.6 μM; AA – 132.5 μM; ADP – 280.6 μM. [1] - In the LDH release assay (an indicator of cellular injury), treatment of platelets with the highest concentration of Jujuboside B (300 μM) did not significantly alter LDH release compared to vehicle, indicating that Jujuboside B does not adversely affect platelet membrane integrity. [1] |
| Enzyme Assay |
- Measurement of TXA₂ formation (as TXB₂): Rat platelet‑rich plasma (2×10⁸ cells/ml) was preincubated with or without Jujuboside B (30, 100, or 300 μM) for 5 min at 37 °C. Collagen (2 μg/ml) was then added and the mixture was incubated for 6 min with stirring. The reaction was stopped by adding 10 mM EDTA. After centrifugation at 12,000×g for 3 min, the amount of TXB₂ in the supernatant was determined using a competitive enzyme immunoassay kit. Jujuboside B significantly and dose‑dependently reduced collagen‑induced TXB₂ production (from 3844.6±28.9 pg/ml in the collagen‑only control to lower levels). Aspirin (300 μM) completely blocked TXB₂ formation. [1]
|
| Cell Assay |
- In vitro platelet aggregation assay: Rat platelet‑rich plasma (PRP, ~2×10⁸ cells/ml) was preincubated with Jujuboside B (30, 100, 300 μM) or vehicle for 5 min in an aggregometer cuvette at 37 °C. Then an aggregating agent (collagen 2 μg/ml, thrombin 0.4 U/ml, AA 100 μM, or ADP 10 μM) was added. Platelet aggregation was recorded for 5 min by the turbidimetric method, and percent change in light transmission was measured relative to a blank (Tyrode buffer without platelets). [1]
- LDH release cytotoxicity assay: PRP was preincubated with Jujuboside B (300 μM) or vehicle for 5 min, then LDH release was measured (exact method not detailed, but stated as an index of cellular injury). No significant increase in LDH release was observed, indicating lack of toxicity at this concentration. [1] |
| Animal Protocol |
- Acute pulmonary thromboembolism model: Male ICR mice (35–40 g) were fasted for 6 h before the experiment. Jujuboside B (10, 30, or 100 mg/kg) or vehicle (10 % Tween‑80‑saline) was administered orally. Two hours later, a mixture of collagen (500 μg/kg) plus epinephrine (12.5 μg/kg) was injected into the tail vein to induce acute thrombosis. Each mouse was observed for 15 min to record paralysis, death, or recovery. Protection against thromboembolism was calculated as: [1 – (paralyzed + dead animals)/total animals] × 100. [1]
|
| Toxicity/Toxicokinetics |
- In the LDH release assay using rat platelets, Jujuboside B at 300 μM did not cause significant LDH release, indicating no acute cytotoxic effect on platelet membrane integrity at this concentration. No other toxicity data (e.g., LD₅₀, hepatotoxicity, protein binding) are reported. [1]
|
| References | |
| Additional Infomation |
Jujuboside B is a triterpenoid compound. Jujuboside B has been reported in jujube, Japanese raisin tree, and wild jujube, and available data are available.
- Jujuboside B is one of the principal saponins in the seeds of Zizypbus jujuba, with a content of 0.05 % in the ethanolic extract. [1] - This study is the first to report any biological activity of Jujuboside B; its antiplatelet and antithrombotic effects were previously unknown. In contrast, jujuboside A (which showed no antiplatelet activity) has known sedative effects. [1] - The mechanism of antiplatelet action of Jujuboside B is at least partially attributed to the inhibition of collagen‑induced TXA₂ production, as evidenced by reduced TXB₂ levels. [1] |
| Molecular Formula |
C52H84O21
|
|---|---|
| Molecular Weight |
1045.21
|
| Exact Mass |
1044.55
|
| CAS # |
55466-05-2
|
| PubChem CID |
24721031
|
| Appearance |
White to off-white solid
|
| Density |
1.4±0.1 g/cm3
|
| Melting Point |
222 - 225 °C
|
| Index of Refraction |
1.628
|
| LogP |
7.53
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
21
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
73
|
| Complexity |
2010
|
| Defined Atom Stereocenter Count |
29
|
| SMILES |
CC(=CC1C[C@@](C)(C2[C@H]3CCC4[C@@]5(C)CC[C@@H](C(C)(C)C5CC[C@@]4(C)[C@@]63C[C@]2(OC6)O1)OC7C(C(C(CO7)O)OC8C(C(C(C(CO)O8)O)O)OC9C(C(C(CO9)O)O)O)OC%10C(C(C(C(C)O%10)O)O)O)O)C
|
| InChi Key |
OAVAUZCEOWCYCC-QEOGCQCLSA-N
|
| InChi Code |
InChI=1S/C52H84O21/c1-22(2)15-24-16-50(8,63)42-25-9-10-30-48(6)13-12-31(47(4,5)29(48)11-14-49(30,7)51(25)20-52(42,73-24)66-21-51)69-45-41(72-44-38(62)35(59)32(56)23(3)67-44)39(27(55)19-65-45)70-46-40(36(60)34(58)28(17-53)68-46)71-43-37(61)33(57)26(54)18-64-43/h15,23-46,53-63H,9-14,16-21H2,1-8H3/t23-,24-,25+,26+,27-,28+,29-,30+,31-,32-,33-,34+,35+,36-,37+,38+,39-,40+,41+,42-,43-,44-,45-,46-,48-,49+,50-,51-,52-/m0/s1
|
| Chemical Name |
(2S,3R,4R,5R,6S)-2-[(2S,3R,4S,5S)-4-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-[[(1S,2R,5R,7S,10R,11R,14R,15S,16S,18R,20S)-16-hydroxy-2,6,6,10,16-pentamethyl-18-(2-methylprop-1-enyl)-19,21-dioxahexacyclo[18.2.1.01,14.02,11.05,10.015,20]tricosan-7-yl]oxy]oxan-3-yl]oxy-6-methyloxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~95.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.39 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.39 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.39 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9567 mL | 4.7837 mL | 9.5675 mL | |
| 5 mM | 0.1913 mL | 0.9567 mL | 1.9135 mL | |
| 10 mM | 0.0957 mL | 0.4784 mL | 0.9567 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
